Advertisements

Cleo (ENDOCRINE THERAPY)

Quick links to important sections

Cleo (ENDOCRINE THERAPY)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cleo (ENDOCRINE THERAPY)

Quick Facts: Cleo (ENDOCRINE THERAPY)

Property Description
Active Ingredients Ethinyl Estradiol and Levonorgestrel
Form Oral Tablet (Prescription Only)
Pharmacological Class Combined Oral Contraceptive (COC)
Typical Use Systemic Contraception and Hormonal Regulation
Origin Synthetic Steroid Hormones

What Type of Medicine is Cleo (ENDOCRINE THERAPY)?

Cleo is classified as a Combined Oral Contraceptive (COC), a widely utilized form of Endocrine Therapy designed for oral administration. The medicine belongs to the established pharmacological class of Sex Hormones and Modulators of the Genital System due to its systemic role in modulating the body’s natural hormonal cycle. As an oral tablet, the medicine is intended for systemic absorption, offering a non-invasive, daily approach to hormonal management. This approach is clinically recognized for its high efficacy when used as directed.


Cleo's Composition: Synthetic Estrogen and Progestin

The core identity of Cleo is rooted in its two active ingredients: Ethinyl Estradiol and Levonorgestrel. This product is a combination of two synthetic steroid hormones; Ethinyl Estradiol serves as the estrogen component, while Levonorgestrel, a well-studied progestin, provides the progesterone-like component. Both components are manufactured derivatives, which grants them specific properties, such as predictable stability and reliable oral bioavailability, differentiating them from natural hormones. The use of this specific dual composition is pharmacologically supported as one of the most thoroughly studied formulations for this therapeutic purpose.


General Purpose of Cleo as Endocrine Therapy

The general purpose of Cleo is to achieve hormonal regulation necessary for systemic contraception. By introducing a regulated supply of synthetic estrogen and progestin, the medication establishes a hormonal environment that signals the body to suppress the natural processes leading to a possible pregnancy. The ultimate functional goal is to establish a predictable, non-fertile hormonal pattern. This mechanism is the core way the medicine provides effective long-term protection, aligning with global health recommendations for birth control.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls - NCBI Bookshelf
  2. Birth control pills: MedlinePlus Medical Encyclopedia
Advertisements

What side effects are possible with Cleo (ENDOCRINE THERAPY)?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety constraints for Cleo, based on governmental regulatory sources. The information is organized by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Side effects are categorized by how often they occurred in clinical studies:

  • Very Common (Affecting 1 in 10 or more people): Hot flushes, arthralgia (joint pain), fatigue, increased sweating, and hypercholesterolaemia (elevated cholesterol levels). These are the most frequent effects of the therapy.
  • Common (Affecting fewer than 1 in 10 people): Headache, dizziness, nausea, gastrointestinal disturbances (e.g., constipation, diarrhea), hypertension, bone pain, and myalgia (muscle aches).
  • Uncommon (Affecting fewer than 1 in 100 people): Thromboembolic events, ischaemic cardiac events, and visual disturbances like blurred vision or cataracts.

Serious Adverse Reactions and Safety Constraints

While uncommon, certain reactions are clinically significant and documented in regulatory labeling:

  • Serious Adverse Reactions (SARs): These include major thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis) and serious ischaemic cardiac events (e.g., myocardial infarction). The official safety profile also notes the potential for bone fractures due to anticipated loss of bone mineral density, requiring monitoring.

  • Population-Specific Contraindications: Cleo is officially contraindicated (must not be used) in specific patient groups, including those with known hypersensitivity to the drug, women who are pregnant or breastfeeding, and women who are premenopausal.

  • Safety Restriction: Patients with severe hepatic impairment (severe liver problems) require close medical supervision due to documented increases in drug exposure.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section addresses the documented symptoms and required actions for a Cleo (Ethinyl Estradiol and Levonorgestrel) overdose, based strictly on official government regulatory documents.

Documented Overdose Manifestations

Overdose of this combined oral contraceptive is generally considered not likely to be life-threatening according to official prescribing information. The clinical signs documented are typically non-severe and self-limiting:

  • Gastrointestinal: Nausea and vomiting.
  • Reproductive: Withdrawal bleeding, which may be heavy or resemble a menstrual period and usually occurs a few days following ingestion.

No serious ill effects have been consistently reported in young children who have accidentally ingested large doses.


Required Emergency Actions

Since an overdose is generally non-severe, the primary regulator-mandated action is to seek immediate guidance:

Action Area Official Regulatory Guidance
Immediate Contact Contact a healthcare provider, pharmacist, or Poison Control Center immediately for specific instructions.
Antidote No specific antidote is documented for this medication.
Management Treatment is entirely symptomatic and supportive. Activated charcoal may be considered in rare, extreme cases.

Hospitalization or an emergency room visit is often not necessary unless otherwise advised by a medical professional or the Poison Control Center.

Advertisements

Therapeutic Uses of Cleo (ENDOCRINE THERAPY)

What Cleo (ENDOCRINE THERAPY) Treats: Main Uses and Benefits

The endocrine therapy Cleo is primarily relevant across key therapeutic domains where situations involving hormonal factors are present to manage complex, disruptive symptomatic patterns and support the prevention of pregnancy. This combination therapy is generally used as an oral contraceptive and is applied in addressing conditions marked by heightened symptoms such as heavy or irregular menstruation and endometriosis.

The medication is commonly used for managing irregular, absent, or unpredictable menstrual cycles in reproductive planning. It is relevant for easing pronounced symptoms like severe menstrual cramps (dysmenorrhea), heavy menstrual bleeding (HMB), and manifestations of hormonal imbalances such as certain types of acne and excessive hair growth (hirsutism).

This therapeutic support is commonly used across conditions presenting with acute or episodic manifestations, helping patients cope more steadily with difficult, recurring episodes. This benefit supports general well-being and helps improve day-to-day comfort during symptomatic periods.

“This medication is commonly used to help patients cope with irregular cycles and ease the overall burden of painful or excessive symptomatic manifestations.”


Quick Fact: Symptom Management

Symptom Cluster Patient Benefit
Heavy Menstrual Bleeding (HMB) Assists with reducing the strain of excessive blood loss.
Dysmenorrhea Is relevant for easing pronounced pain and discomfort.
Acne & Hirsutism Supports managing noticeable functional strain from hormonal manifestations.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Cleo (Ethinyl Estradiol and Levonorgestrel) is indicated for use by postmenarchal females of reproductive potential for the prevention of pregnancy. Official regulatory labeling imposes absolute restrictions based on serious health risks, primarily related to vascular, hepatic, and hormone-dependent conditions.


Populations for whom Use is Contraindicated

Use is absolutely prohibited in females with the following conditions:

  • High risk of arterial or venous thrombotic diseases, including current or history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or coronary artery disease.
  • Cigarette smoking if over 35 years of age, due to a significantly increased risk of serious cardiovascular events.
  • Known or suspected pregnancy; the medicine must be discontinued immediately if pregnancy is confirmed.
  • Breast cancer or other known estrogen- or progestin-sensitive cancers.
  • Liver tumors or severe (decompensated) cirrhosis.
  • Migraine with aura at any age.
  • Uncontrolled hypertension or diabetes with vascular damage.

Eligibility-Related Restrictions

  • Use is not recommended for women who are breastfeeding, as it may decrease milk production.
  • The medicine should be started no earlier than four weeks postpartum in non-breastfeeding women due to the elevated risk of thromboembolism.
  • Use is not indicated in postmenopausal women.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The endocrine therapy product, often referred to as Cleo in this context (Elacestrant), has documented interactions primarily involving enzyme and transporter systems in the body. Concomitant use with certain medicinal products can significantly alter the exposure of this drug, which may affect its efficacy or the potential for side effects.

Interacting Product Categories

The most clinically relevant interactions involve medicines that are classified as Strong or Moderate CYP3A4 Inducers or Inhibitors. This is because the endocrine therapy drug is primarily metabolized by the CYP3A4 enzyme system.

  • CYP3A4 Inhibitors: Co-administration with strong or moderate CYP3A4 inhibitors should be avoided, as this may increase the exposure of Cleo, potentially increasing the risk of adverse reactions. Specific dose adjustments are required if a strong or moderate CYP3A4 inhibitor is considered necessary.
  • CYP3A4 Inducers: The concurrent use of strong or moderate CYP3A4 inducers must also be avoided. Inducers decrease the exposure of the drug, which may reduce its effectiveness. Alternative medicinal products with no or minimal potential to induce CYP3A4 should be considered.

Additionally, this endocrine therapy product acts as an inhibitor of the P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) efflux transporters. This means that using it alongside medicines that are substrates for P-gp or BCRP may increase the concentrations of those co-administered drugs. This may necessitate a dosage reduction for the P-gp or BCRP substrate drug to manage potential adverse reactions.

Advertisements

Mechanism of Action

Cleo, an example of a selective estrogen receptor modulator (SERM), primarily targets the Estrogen Receptor (ER), specifically the ER-alpha and ER-beta subtypes, which are nuclear receptors.

The agent acts as a competitive antagonist for the ligand-binding domain of the ER within targeted tissues. It occupies the receptor, thereby sterically preventing the binding of endogenous estrogens, such as 17beta-estradiol (E2).

This blockade inhibits the E2-mediated conformational change necessary for the activated ER dimer to translocate to the nucleus and bind to Estrogen Response Elements (EREs) on the DNA promoter regions of target genes. By precluding this genomic signaling pathway, Cleo prevents the recruitment of coactivator proteins, resulting in the suppression of ER-regulated gene transcription. The downstream cascade involves a reduction in the synthesis of proteins involved in cellular proliferation. The system-level consequence is the modulation of estrogen-driven gene expression in target tissues, effectively inhibiting the ER-mediated regulatory mechanism.

Advertisements

Dosage and Administration Information

How to Use Cleo (ENDOCRINE THERAPY)

The medicine is a Combined Oral Contraceptive (COC) containing Ethinyl Estradiol and Levonorgestrel and is utilized through systemic oral administration as a long-term hormonal therapy. Usage is defined by strict adherence to an official daily dosing schedule to maintain consistent hormone levels. The general instruction is to take one tablet daily by mouth at the same time every day at intervals not exceeding 24 hours.

Standard Administration Cycles

The administration schedule is structured into two primary cyclic regimens:

  • 28-Day Cycle: This involves taking the active tablets for 21 consecutive days, followed by a 7-day period during which inactive or placebo tablets are taken. The next 28-day pack must be started immediately following the previous one.
  • Extended 91-Day Cycle: This regimen requires taking the active tablets for 84 consecutive days, followed by a 7-day period for tablets containing either low-dose estrogen or placebo.

The tablets must be taken in the sequence directed on the packaging and can be taken without regard to meals.

Initiation and Adherence Protocols

Official instructions specify approved methods for initiating the first course, such as the Day 1 Start or Sunday Start. If starting late, such as with the Sunday Start, an additional non-hormonal method of contraception must be used for the first seven consecutive days of active tablet use.

Missed Doses: If a single active tablet is missed by more than 12 hours, specific steps, including the use of back-up non-hormonal contraception, are required for the subsequent 7 days. The use of Cleo in non-breastfeeding women is officially recommended no earlier than four weeks after delivery.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Cleo (ENDOCRINE THERAPY)

Evidence for use in Contraception and Cycle Regulation

The research exploring this therapy has primarily involved large Randomized Controlled Trials (RCTs) conducted in healthy women of reproductive potential. These trials were designed to evaluate outcomes related to pregnancy incidence rates and the monitoring of bleeding patterns. Studies reported measurements related to the prevention of pregnancy across the observed cycles. Regulatory reviews have summarized this effectiveness data based on a large volume of available clinical evidence.

The available evidence for this primary function is broadly supported by extensive clinical evidence. However, long-term outcomes of use extending beyond two years are often characterized by observational settings rather than extended randomized trials. Evidence for specific subgroups with certain underlying health conditions is often drawn from broader post-marketing surveillance rather than dedicated RCTs.


Evidence for Symptom Management: Menstrual Cramps (Dysmenorrhea) and Heavy Bleeding (HMB)

Research has explored the medicine's use in conditions associated with cycles of stability and flare-ups, such as severe menstrual cramps (dysmenorrhea). Studies focused on outcomes related to physical discomfort, using validated scales to measure pain intensity and tracking patient-reported use of analgesic medication. Studies conducted during periods of increased symptom activity reported measurements of changes in pain scores among participants. Reviews reported patterns observed in studies related to changes in blood loss volume (HMB) and related changes in iron deficiency markers. The evidence level for this use is generally described as moderate.


Evidence for Managing Hormonal Manifestations: Acne and Hirsutism

Clinical trials and systematic reviews tracked changes in acne lesion counts and assessed hair growth patterns (hirsutism). The medicine was studied for managing symptoms related to systemic or functional imbalance. Clinical trials reported observations of changes in acne lesion counts over several cycles of use. Research related to hirsutism generally required intermediate-to-long-term follow-up (six months or longer) to collect sufficient data for analysis. Systematic reviews acknowledged that findings may vary depending on the specific dose and type of progestin used in the combination.


Evidence for Symptom Management in Endometriosis

The research exploring this medicine's role in endometriosis relies largely on Systematic Reviews and Observational Studies, often using continuous or extended-cycle regimens. Studies monitored patient-reported outcomes describing perceived discomfort, specifically assessing changes in pelvic pain scores. The data collected is reported as being primarily related to symptom measurements and not to modifications of the underlying disease pathology itself. The certainty remains low for this application, and evidence quality varies across studies, indicating that more extensive research is still needed.

Key Studies & References

  1. Comparison of Combined Parenteral and Oral Hormonal Contraceptives: A Systematic Review and Meta-Analysis of Randomized Trials
  2. ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cleo (ENDOCRINE THERAPY) (FAQ)


Q: How quickly should I expect to notice anything after starting Cleo?

A: Regulatory documents state that to achieve maximum effectiveness for pregnancy prevention, official instructions include the use of a back-up, non-hormonal contraceptive method for the first seven consecutive days of taking the active tablets. This is described as the time needed for the medicine to establish the intended level of protection.

Q: What food or drinks might interfere with Cleo?

A: Official administration instructions state that the tablets may be taken without regard to meals. Regulatory documents do not specifically list common foods or drinks that must be avoided. Drug interactions are focused on certain types of medicines that may alter the way Cleo is processed by the body.

Q: Is Cleo intended for temporary or long-term use?

A: According to official product information, Cleo is indicated for use by females of reproductive potential to prevent pregnancy. This use aligns with a pattern of long-term hormonal regulation, consistent with systemic contraception.

Q: How long does Cleo stay in your system after stopping it?

A: Regulatory documents describe the elimination rate using a measure called the half-life. The half-life for one component, levonorgestrel, is approximately 36 hours, and for ethinyl estradiol, it is about 18 hours at steady state. This suggests the medicine's components decrease to undetectable levels over a period of several days.

Q: Is it true that Cleo can affect mood or cause anxiety?

A: Official documentation lists depression as a potential adverse reaction or a condition that requires monitoring if symptoms change or worsen. Anxiety, however, is not specifically named as an adverse reaction in the regulatory labeling.

Q: What is the risk of a severe allergic reaction to Cleo?

A: Severe allergic reactions, known as hypersensitivity reactions, are noted as possible adverse reactions in official labeling. These reactions are clinically significant and require prompt medical evaluation. Symptoms can include skin rash, hives, or swelling of the face, lips, tongue, or throat.

Q: Does taking Cleo affect fertility?

A: The primary indication of the medicine is the prevention of pregnancy. Studies and official information indicate that no permanent impairment of fertility has been described in the core regulatory label after the medicine is discontinued.

Q: Is Cleo considered a targeted therapy?

A: Cleo is officially classified as a Combined Oral Contraceptive (COC) and belongs to the pharmacological class of Sex Hormones and Modulators. The term 'targeted therapy' is not typically used in the official classification for this type of medication.

Q: Are there any known interactions between Cleo and herbal supplements like St. John's Wort?

A: St. John's Wort is specifically mentioned in regulatory sources due to its potential to reduce the effectiveness of the contraceptive hormones. Official information advises that if St. John’s Wort is used concurrently, alternative or back-up contraception should be utilized.

Q: Is Cleo available as a generic medicine?

A: The active ingredients in Cleo, Levonorgestrel and Ethinyl Estradiol, are produced by multiple manufacturers. This is consistent with the availability of generic versions of the medicine.

Q: What should I do if I get a headache after taking Cleo?

A: Headache is a common adverse reaction. The label advises that a significant change in the pattern or severity of headaches should be evaluated by a healthcare provider, as this may be a reason for discontinuation of the medicine.

Q: Why does Cleo have a Black Box Warning, if it does?

A: Cleo carries a Boxed Warning, which is the strongest safety warning from the FDA. The warning describes the increased risk of Serious Cardiovascular Events, particularly in women over 35 years of age who smoke.

Q: Is Cleo used to treat more than one condition?

A: Cleo is officially indicated only for the prevention of pregnancy. However, regulatory documents mention that clinical studies have also examined its use for managing symptoms related to conditions such as dysmenorrhea (menstrual cramps) and acne.

Q: What patient groups were excluded from the main Cleo studies?

A: Regulatory documents related to clinical trials indicate that patient groups who have existing contraindications, such as a history of blood clots or who are over 35 and smoke, are generally excluded or subject to restrictions in the main studies.

Q: Does Cleo need special storage conditions, like refrigeration?

A: Official storage instructions state that the tablets must be kept at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must not be frozen, and refrigeration is not required.

Q: Can I take Cleo if I have diabetes?

A: The medicine is officially contraindicated in females who have uncontrolled diabetes or diabetes that has resulted in vascular damage. The regulatory label notes that monitoring blood glucose levels may be appropriate for prediabetic and diabetic females.

Q: How does Cleo's use condition change if I have kidney issues?

A: No formal studies have been conducted to evaluate how kidney disease affects the medicine's disposition. However, the label advises monitoring due to the potential for fluid retention in patients with kidney issues.

Q: Why is Cleo sometimes prescribed with another medicine?

A: Official labeling advises that if certain medicines known as 'enzyme inducers' are used concurrently, a back-up or alternative method of contraception should be used. This is to ensure the effectiveness of Cleo is not reduced by the other medicine.

Q: What happens if I forget to pick up my Cleo prescription refill on time?

A: If a new pill pack is not started immediately after the previous one, back-up non-hormonal contraception is required to be used. This back-up method must be used until 7 consecutive active tablets have been taken in the new pack.

Q: Is Cleo associated with any vision or eye problems?

A: Serious adverse reactions related to vascular events can present as sudden vision loss. Common side effects may also include problems with contact lenses or the onset of migraine headaches with associated visual disturbances.

Q: How can I tell if my Cleo tablet is expired?

A: The medicine has a formal shelf-life determined by the manufacturer, which is marked on the outer package. The medicine should not be used past this printed expiration date, which represents the period during which the manufacturer guarantees the product's stability and effectiveness.

Advertisements

How should Cleo (ENDOCRINE THERAPY) be stored and disposed of?

Cleo tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted up to 30 C (86 F). The medicine must not be frozen and must be kept in its original, tightly closed container and protected from light, heat, and moisture. To maintain stability, the tablets must be kept in the packaging they came in. The medicine must be kept out of the reach of children and stored in a locked location. Unused or outdated medicine should not be kept. Disposal requires consulting a healthcare professional or following local disposal guidelines; the tablets must not be flushed down the toilet or released into the sanitary sewer system to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cleo (ENDOCRINE THERAPY) found in:

A-Z Index: